MX2018005620A - Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. - Google Patents
Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina.Info
- Publication number
- MX2018005620A MX2018005620A MX2018005620A MX2018005620A MX2018005620A MX 2018005620 A MX2018005620 A MX 2018005620A MX 2018005620 A MX2018005620 A MX 2018005620A MX 2018005620 A MX2018005620 A MX 2018005620A MX 2018005620 A MX2018005620 A MX 2018005620A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- specific demethylase
- lysine specific
- compositions
- lysine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen en la presente formas amorfas y cristalinas de sales farmacéuticamente aceptables del inhibidor de demetilasa-1 especifico de lisina, 4-[2-(4-amino-piperidin-1-i1)-5-(3-fluoro-4- metoxi-feni1)-1-metil-6-oxo-1,6-dihidro-pirimidin-4-111-2-fluorob enzonitrilo. También se describen composiciones farmacéuticas adecuadas para administración a un mamífero que incluye el inhibidor de demetilasa-1 específico de lisina, y métodos para utilizar el inhibidor de demetilasa-1 específico de lisina para tratar enfermedades o condiciones que están asociadas con la actividad de demetilasa-1 especifica de lisina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562251507P | 2015-11-05 | 2015-11-05 | |
PCT/US2016/060694 WO2017079670A1 (en) | 2015-11-05 | 2016-11-04 | Compositions comprising an inhibitor of lysine specific demethylase-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018005620A true MX2018005620A (es) | 2018-08-01 |
Family
ID=58662888
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005620A MX2018005620A (es) | 2015-11-05 | 2016-11-04 | Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. |
MX2020004894A MX2020004894A (es) | 2015-11-05 | 2016-11-04 | Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004894A MX2020004894A (es) | 2015-11-05 | 2016-11-04 | Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. |
Country Status (20)
Country | Link |
---|---|
US (4) | US9828358B2 (es) |
EP (1) | EP3371152B1 (es) |
JP (1) | JP6995043B2 (es) |
CN (1) | CN108473442B (es) |
AR (1) | AR106612A1 (es) |
AU (1) | AU2016349707B2 (es) |
CA (1) | CA3004300C (es) |
CY (1) | CY1124078T1 (es) |
DK (1) | DK3371152T3 (es) |
ES (1) | ES2846951T3 (es) |
HR (1) | HRP20210144T8 (es) |
HU (1) | HUE053449T2 (es) |
LT (1) | LT3371152T (es) |
MX (2) | MX2018005620A (es) |
PL (1) | PL3371152T3 (es) |
PT (1) | PT3371152T (es) |
RS (1) | RS61404B1 (es) |
SI (1) | SI3371152T1 (es) |
TW (1) | TW201720808A (es) |
WO (1) | WO2017079670A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20161438A1 (es) * | 2014-05-01 | 2017-01-18 | Celgene Quanticel Res Inc | Inhibidores de desmetilasa 1 especifica a lisina |
EP3371152B1 (en) * | 2015-11-05 | 2020-12-23 | Celgene Quanticel Research, Inc. | Compositions comprising an inhibitor of lysine specific demethylase-1 having a pyrimidine ring and its use in the treatment of cancer |
EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
US20200069677A1 (en) | 2016-12-09 | 2020-03-05 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
BR112020000827A2 (pt) | 2017-08-03 | 2020-07-21 | Oryzon Genomics, S.A. | métodos de tratamento de alterações de comportamento |
US20220151998A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
JP2022526755A (ja) | 2019-03-20 | 2022-05-26 | オリソン ヘノミクス,ソシエダ アノニマ | 化合物バフィデムスタット(vafidemstat)などkdm1a阻害剤を使用した注意欠陥多動性障害の処置方法 |
MX2021015447A (es) * | 2019-06-13 | 2022-04-06 | Celgene Corp | Métodos de tratamiento del cáncer dirigidos a tumores fríos. |
US20220249528A1 (en) * | 2019-06-20 | 2022-08-11 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Kdm1a阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
WO2021247977A1 (en) * | 2020-06-05 | 2021-12-09 | Celgene Quanticel Research, Inc. | Methods of treating prostate cancer |
ES2919083R1 (es) * | 2020-06-29 | 2022-07-26 | Celgene Quanticel Res Inc | Métodos de tratamiento de cáncer de próstata |
WO2022214303A1 (en) | 2021-04-08 | 2022-10-13 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
CA2513414A1 (en) * | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
AU2003216591A1 (en) * | 2002-04-10 | 2003-10-20 | Orichid Chemicals And Pharmaceuticals Limited | Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
US20070270446A1 (en) * | 2004-10-06 | 2007-11-22 | Smithkline Beecham Corporation | Reversed Pyrimidinone Compounds as Calcilytics |
AR073760A1 (es) | 2008-10-03 | 2010-12-01 | Astrazeneca Ab | Derivados heterociclicos y metodos de uso de los mismos |
US10093646B2 (en) * | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
PE20161438A1 (es) * | 2014-05-01 | 2017-01-18 | Celgene Quanticel Res Inc | Inhibidores de desmetilasa 1 especifica a lisina |
EP3371152B1 (en) * | 2015-11-05 | 2020-12-23 | Celgene Quanticel Research, Inc. | Compositions comprising an inhibitor of lysine specific demethylase-1 having a pyrimidine ring and its use in the treatment of cancer |
-
2016
- 2016-11-04 EP EP16863111.7A patent/EP3371152B1/en active Active
- 2016-11-04 PT PT168631117T patent/PT3371152T/pt unknown
- 2016-11-04 SI SI201631055T patent/SI3371152T1/sl unknown
- 2016-11-04 LT LTEP16863111.7T patent/LT3371152T/lt unknown
- 2016-11-04 CN CN201680076854.5A patent/CN108473442B/zh active Active
- 2016-11-04 HU HUE16863111A patent/HUE053449T2/hu unknown
- 2016-11-04 US US15/344,426 patent/US9828358B2/en active Active
- 2016-11-04 CA CA3004300A patent/CA3004300C/en active Active
- 2016-11-04 ES ES16863111T patent/ES2846951T3/es active Active
- 2016-11-04 RS RS20210094A patent/RS61404B1/sr unknown
- 2016-11-04 MX MX2018005620A patent/MX2018005620A/es active IP Right Grant
- 2016-11-04 PL PL16863111T patent/PL3371152T3/pl unknown
- 2016-11-04 DK DK16863111.7T patent/DK3371152T3/da active
- 2016-11-04 MX MX2020004894A patent/MX2020004894A/es unknown
- 2016-11-04 JP JP2018522953A patent/JP6995043B2/ja active Active
- 2016-11-04 WO PCT/US2016/060694 patent/WO2017079670A1/en active Application Filing
- 2016-11-04 AU AU2016349707A patent/AU2016349707B2/en active Active
- 2016-11-07 AR ARP160103391A patent/AR106612A1/es unknown
- 2016-11-07 TW TW105136105A patent/TW201720808A/zh unknown
-
2017
- 2017-10-25 US US15/793,512 patent/US10047069B2/en active Active
-
2018
- 2018-07-10 US US16/032,002 patent/US10316016B2/en active Active
-
2019
- 2019-06-10 US US16/436,541 patent/US10703739B2/en active Active
-
2021
- 2021-01-27 HR HRP20210144TT patent/HRP20210144T8/hr unknown
- 2021-01-28 CY CY20211100072T patent/CY1124078T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018005620A (es) | Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. | |
MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
MX2021009673A (es) | Moduladores de ror-gamma. | |
PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
PH12016502005B1 (en) | Compounds and compositions for inducing chondrogenesis | |
MX2015012850A (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
EA033689B9 (ru) | Ингибиторы g12c kras | |
MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
EA201791021A1 (ru) | 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ | |
PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
MX2017001869A (es) | Formas cristalinas de un modulador de receptor de estrogeno. | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
UA102355U (ru) | Способ лечения рецидивирующей формы фибрилляции предсердий у больных с ишемической болезнью сердца | |
IN2014DE00822A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |